China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on China Resources Sanjiu Medical & Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how China Resources Sanjiu Medical & Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with China Resources Sanjiu Medical & Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
China Resources Sanjiu Medical & Pharmaceutical Co Ltd (CR Sanjiu), a subsidiary of China Resources Pharmaceutical Group Ltd, researches, develops, manufactures, and commercializes pharmaceutical products, including traditional Chinese medicine, OTC, and prescription drugs. The company's product portfolio includes OTC drugs, antibiotic drugs, and active pharmaceutical ingredients(APIs), Chinese prescription medicines, traditional Chinese medicine (TCM), and formula granules. It also provides packaging, printing, international trade business, and other services. Its CHC health consumer products covering categories such as colds, gastrointestinal, dermatology, hepatobiliary, pediatrics, orthopedics, and gynecology. The company offers its products under the 999 brand and the Sanjiu Weitai series, among others. The company has a presence in China and also exports to overseas markets. CR Sanjiu is headquartered in Shenzhen, China.
Headquarters
China
Address
Guanlan Hi-Tech Park, No. 1 Guanqing Road, Longhua New District, Shenzhen, Guangdong, 518110
Website
www.999.com.cn
Telephone
86 755 83360999
No of Employees
30,304
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000999 (SHE)
Revenue (2024)
$4.4B
14.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.6%
(2024 vs 2023)
Market Cap*
$6.2B
Net Profit Margin (2024)
XYZ
-11.2%
(2024 vs 2023)
* As of and is in US$
China Resources Sanjiu Medical & Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Antibiotics and Generic Drugs | Service: | 999 |
| Non-Prescription Drugs | Medical Products Distribution | 777 |
| Traditional Chinese Medicine Prescription Drugs | Tianhe | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In September, Puyouke secured approval from the National Medical Products Administration for a new indication, thrombolytic therapy for acute ischemic stroke. |
| 2025 | Contracts/Agreements | In August, the company and Borrui Pharmaceuticals signed a collaboration agreement on the research and development, registration, production, and commercialization of BGM0504 injection in mainland China (excluding Hong Kong, Macau, and Taiwan). |
| 2025 | New Product Approvals | In August, the company's Minoxidil Liniment received marketing approval from the National Medical Products Administration. |
Competitor Comparison
| Key Parameters | China Resources Sanjiu Medical & Pharmaceutical Co Ltd | Yunnan Baiyao Group Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | Chongqing Taiji Industry (Group) Co Ltd | Tibet Rhodiola Pharmaceutical Holding Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenzhen | Kunming | Lianyungang | Chongqing | Lasa |
| State/Province | Guangdong | Yunnan | Jiangsu | Chongqing | Tibet |
| No. of Employees | 30,304 | 9,286 | 20,602 | 10,864 | 671 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Qiu Huawei | Chairman | Executive Board | 2021 | 59 |
| Zhou Hui | Director; ; Chief Compliance Officer; Vice President | Executive Board | 2013 | 55 |
| Xing Jian | Chief Financial Officer; Secretary | Senior Management | 2025 | 49 |
| Wu Wenduo | President; Director | Executive Board | 2024 | 53 |
| Mai Yi | Vice President | Senior Management | 2015 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer